CTIS2022-502018-10-00招募中1 期
Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (pilot cohort study with short walking objectives) - PERIPATEI - RBHP 2022 DUALE
niversity Hospital Of Clermont-Ferrand0 个研究点目标入组 55 人开始时间: 2022年9月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patient, man or woman aged 50 to 70, suffering from uni- or bilateral idiopathic osteoarthritis of the hip or knee, whose diagnosis is confirmed by compliance with the radio-clinical criteria of the American College of Rheumatology (Altman et al., 1986): Joint pain felt for at least half the time during the last 3 months prior to inclusion /Morning stiffness lasting less than 30 minutes or joint crackling / Kellgren and Lawrence stage = 2 attested by an available x-ray, Walking pain rated at least 4 on a scale of 0 (no pain) to 10 (worst imaginable pain), associated with consequent limitation of walking ability (declarative), Weekly number of significant trips (walking of at least 20 minutes or 1000 meters) < 3, Ability to comply with protocol requirements and provide informed consent to participate in research, Comprehension and fluent writing of the French language, Coverage by a Social Security scheme
排除标准
- •Pregnant or breastfeeding woman, Forecast during the period of the initiation study of a non-pharmacological analgesic treatment different from that proposed by the protocol, such as physiotherapy, behavioral therapy (self-management of pain, hypnosis, sophrology, meditation, mindfulness), Use of a unicompartmental unloading hinged orthosis (indicated for pain predominant in a femoro-tibial compartment of the knee) initiated during the 2 months preceding inclusion, or scheduled during the study period (continuation of older use is possible), Intra-articular injection of glucocorticoid into the affected joint(s), during the 2 months preceding inclusion, or scheduled during the study period., Visco-supplementation in one or more joints concerned, during the 2 months preceding inclusion, or scheduled during the study period, Intramuscular injection of glucocorticoid during the month preceding inclusion, Interventional surgery on one or more joints concerned, in the 6 months preceding the scheduled inclusion during the study period, Arthroscopy of one or more joints concerned, within 3 months prior to inclusion or scheduled during the study period, Other major surgery scheduled during the study period, Possible progressive hematological or cancerous pathology (with the exception of a basal cell carcinoma for which total excision was recently performed), Immunodepression, Person under guardianship, curatorship or safeguard of justice, or deprived of freedoms, Causal pathology of the suspected or proven arthropathy, such as: inflammatory rheumatism, septic arthritis, recent osteonecrosis, hemochromatosis, Wilson's disease, gout, acromegaly, Other general osteo-articular pathology such as Paget's or Reiter's disease, Chronic pain (especially neuropathic) concomitant with joint pain, considered severe enough to be an obstacle to walking, Hypersensitivity to one of the excipients of a treatment provided for in the protocol, which cannot be replaced by an equivalent formulation, History of hypersensitivity reactions such as: angioedema, asthma, bronchospasm, nasal polyps, rhinitis, urticaria, or other allergic reactions triggered by taking NSAIDs or acetylsalicylic acid, History of haemorrhage or gastrointestinal perforation during previous treatment with NSAIDs, Active peptic ulcer, history of peptic ulcer or recurrent bleeding (2 or more distinct episodes of documented bleeding or ulceration)., Severe hepatocellular insufficiency, or liver transplantation, or plasma levels of hepatic transaminases exceeding two and a half times the upper limit of normal according to laboratory standards, Renal impairment defined by an estimated creatinine clearance < 60 mL/min (MDRD) or renal transplantation, or serum creatinine exceeding one and a half times the upper limit of the normal according to laboratory standards, Uncontrolled high blood pressure, Weight < 40 kg or body mass index (BMI) < 19 kg.m–2, Congestive heart failure (EF < 40%), Insulin-requiring diabetes, Known bleeding disorder, Alcohol dependence or known drug use (e.g. non-prescription opioids, amphetamines, cannabis, cocaine, phencyclidine, etc.)., Regular intake of strong or substitute opioids (occasional intake of a strong opioid, or regular intake of tramadol or a weak opioid and paracetamol combination is possible)., Hypersensitivity to paracetamol, Hypersensitivity to proton pump inhibitors, if protocol-specified clinical conditions indicate such treatment, According
研究者
相似试验
已完成
不适用
Walking rehabilitation using a supporting device for hip joint movement:effects on patients with hemiplegic gaitstrokeJPRN-UMIN000041466Suita Municipal Hospital5
已完成
4 期
Prehabilitation intervention for patients undergoing elective colectomy: a prospective observational study utilizing a leucine-enriched beveragesarcopeniaJPRN-jRCT1091220321Otsuka Pharmaceutical Factory,Inc.80
已完成
不适用
Robot-assisted walking training for patients with subacute strokeKCT0001837Wonkwang University Hospital20
已完成
不适用
Stepped movement-oriented rehabilitation and aftercare in patients with inflammatory and non-inflammatory diseases of the musculoskeletal systemM51M53M54M05M06M07M45M46Other intervertebral disc disordersOther dorsopathies, not elsewhere classifiedDorsalgiaSeropositive rheumatoid arthritisOther rheumatoid arthritisPsoriatic and enteropathic arthropathiesAnkylosing spondylitisOther inflammatory spondylopathiesDRKS00007920Deutsche Rentenversicherung Bund801
已完成
不适用
Effects of physical rehabilitation on muscle function and gait parameters of patients with intermittent claudication.peripheral artery diseaseIntermittent claudicationPhysical Medicine / Rehabilitation - PhysiotherapyCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12621000780853WROVASC - Integrated Center for Cardiovascular Medicine80